fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosisInventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from…

1 month ago
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

March 03, 2025 09:27 ET  | Source: Pliant Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) --…

2 months ago
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary FibrosisPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis

February 07, 2025 16:58 ET  | Source: Pliant Therapeutics, Inc. Following DSMB recommendation, the Company has voluntarily paused enrollment and…

3 months ago